Offices:
Reykjavik
Investors:
we tracked 4 investors
You need an account to access this feature.
Login or create one from
here.
(it takes 20 seconds)
Total investments received (USD) - we tracked 1 transaction
You need an account to access this feature.
Login or create one from
here.
(it takes 20 seconds)
3Z was founded in 2008 by Karl Karlsson, Reykjavik University, and Haraldur Thorsteinsson. It originates from RU neurolab, a Reykjavik University based neuroscience laboratory, in which a zebrafish model of sleep has been in development since 2006.
Karl Karlsson is a professor at the School of Science and Engineering at Reykjavik University. He obtained a Phd in Behavioral Neuroscience from Iowa University in 2005. In 2006 Karlsson started RU Neurolab, a laboratory focused on the neurobiology of sleep and wake. Haraldur Thorsteinsson joined RU Neurolab in 2008. He received an MSc. in Neuropsychology from the University of Maastricht in 2008.
At RU Neurolab a zebrafish model for studying sleep and wake physiology has been developed and is currently employed in high throughput screening. Other core methods employed in the lab include automated behavioral analysis, basic genetics, histology and in vivo/in vitro electrophysiology.
Companies with similar profile to 3Z Pharmaceuticals:
| Company | Criteria |
|---|
 Asarina Pharma44% | - Similar verticals: Health services, Pharma
- Similar business models: B2B
- Minim one investor from outside Scandinavia: Yes
|
| Ilya Pharma 44% | - Similar verticals: Health services, Pharma
- Similar business models: B2B
- Total raised in a similar range: < 1M USD
|
 Cope IT43% | - Similar verticals: Health services
- Similar business models: B2B
- Total raised in a similar range: < 1M USD
- Minim one investor from outside Scandinavia: Yes
|
| Trialbee 34% | - Similar verticals: Health services, Pharma
- Similar business models: B2B
|
 Avexxin34% | - Similar verticals: Health services, Pharma
- Similar business models: B2B
|
| Athera 34% | - Similar verticals: Health services, Pharma
- Similar business models: B2B
|
 Mint Solutions34% | - Similar verticals: Health services
- At least one vc investor: NSA Ventures
- Minim one investor from outside Scandinavia: Yes
|
| Vironova 34% | - Similar verticals: Health services, Pharma
- Similar business models: B2B
|
| Vaccibody 34% | - Similar verticals: Health services, Pharma
- Similar business models: B2B
|
| MagCath 33% | - Similar verticals: Health services
- Similar business models: B2B
- Total raised in a similar range: < 1M USD
|
 Blueprint Genetics33% | - Similar verticals: Health services
- Similar business models: B2B
- Minim one investor from outside Scandinavia: Yes
|
| Mevia 33% | - Similar verticals: Health services
- Similar business models: B2B
- Total raised in a similar range: < 1M USD
|
| Modus Therapeutics 33% | - Similar verticals: Health services
- Similar business models: B2B
- Minim one investor from outside Scandinavia: Yes
|
| BC Platforms 33% | - Similar verticals: Health services
- Similar business models: B2B
- Minim one investor from outside Scandinavia: Yes
|
| Inhalation Sciences 33% | - Similar verticals: Health services
- Similar business models: B2B
- Total raised in a similar range: < 1M USD
|
| Optomed 33% | - Similar verticals: Health services
- Similar business models: B2B
- Minim one investor from outside Scandinavia: Yes
|
| Synoste Oy 33% | - Similar verticals: Health services
- Similar business models: B2B
- Minim one investor from outside Scandinavia: Yes
|
| Klinik 33% | - Similar verticals: Health services
- Similar business models: B2B
- Total raised in a similar range: < 1M USD
|
| Absolute Liquid Solutions 33% | - Similar verticals: Health services
- Similar business models: B2B
- Total raised in a similar range: < 1M USD
|
| No Isolation 33% | - Similar verticals: Health services
- Similar business models: B2B
- Total raised in a similar range: < 1M USD
|
